DI-UMONS : Dépôt institutionnel de l’université de Mons

Recherche transversale
Rechercher
(titres de publication, de périodique et noms de colloque inclus)
2013-04-01 - Article/Dans un journal avec peer-review - Français - 7 page(s)

Lechien Jérome , Kindt Nadège , Costa Pedro, Preillon Julie, Chantrain Gilbert, Laurent Guy , Saussez Sven , "MIF in Head and Neck cancer: a new therapeutic target ?" in Revue de Laryngologie - Otologie - Rhinologie, 134, 2, 67-74

  • Edition : Editions Doin Deren et Cie, Bordeaux (France)
  • Codes CREF : Cancérologie (DI3349)
  • Unités de recherche UMONS : Anatomie et Biologie cellulaire (M112)
  • Instituts UMONS : Institut des Sciences et Technologies de la Santé (Santé)

Abstract(s) :

(Anglais) Macrophage migration inhibitory factor is a critical pro-inflammatory cytokine produced by cells of innate and adaptive immune system. This protein is traditionally known for its involvement in systemic, autoimmune and metabolic diseases such as obesity, atherosclerosis, diabetes, rheumatoid arthritis and systemic lupus erythematosus. Several studies have also shown its role in chronic gastritis and chronic pancreatitis, especially where MIF may constitute an important link between chronic inflammatory process and carcinogenesis. Other studies have demonstrated that MIF plays a key role in cell cycle regulation and in the pathogenesis of many cancers. Recently, MIF has been studied in the upper aerodigestive tract cancer for its involvement in tumor progression, invasion, proliferation and cell motility. In addition, MIF appears to be a mediator in angiogenesis and in the development of metastasis and locoregional lymph node, which are often associated with a poor prognosis. However, the main effects of MIF are mediated by the CD74 receptor, conventionally known as chaperone of major histocompatibility locus (MHC II). MIF binding to its receptor is responsible for the activation of several signaling pathways (ERK1 / 2 - MAPK, JAB1 - CSN5, PI3K - Akt), the inhibition of p53 and the stimulation of angiogenic factors including VEGF and IL-8. Moreover, it appears that overexpression of MIF causes a reduction of the anti-tumor activity of the immune system. In addition, the CD74 overexpression is responsible for inhibition of the immune response by a deficiency in the antigen presentation. Finally, MIF could be an interesting biomarker in the diagnosis and monitoring of upper aero-digestive tract cancers. In this paper, we assess the state of knowledge on the involvement of MIF in upper aero-digestive tract cancers and we analyze the therapeutic perspectives.


Mots-clés :
  • (Anglais) Cancer
  • (Anglais) Head and neck
  • (Anglais) MIF
  • (Anglais) CD74